Use of Risperidone in Children With Autism, Bipolar Disease, or Schizophrenia

Marcia L. Buck, Pharm.D., FCCP

Pediatr Pharm. 2008;14(1) 

In This Article


On October 6, 2006, the Food and Drug Administration (FDA) announced the approval of risperidone, an atypical antipsychotic, as the first drug to treat irritability and aggression in children with autism. On August 22, 2007, the FDA-approved indications for risperidone were expanded to include treatment of bipolar disorder in children 10 years of age and older and schizophrenia in patients 13 years of age and older.[1] While risperidone has made a significant improvement in the lives of many children, it is associated with a number of potentially serious adverse effects. The decision to initiate therapy should only be made after careful consideration of the benefits and risks and a thorough discussion with the patient's family. This issue of Pediatric Pharmacotherapy will provide an overview of the studies conducted with risperidone in children and review its pharmacokinetics, drug interactions, and adverse effects.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.